Verzenio (abemaciclib)

pCPA File Number: 23277
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) in postmenopausal women as initial endocrine-based therapy.
Sponsor/Manufacturer:
Eli Lilly Canada Inc.
CDA-AMC Project Number:
PC0400-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable